{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:43:33Z","timestamp":1791855813069,"version":"4.3.4"},"reference-count":9,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170735"],"award-info":[{"award-number":["82170735"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000679"],"award-info":[{"award-number":["82000679"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930120"],"award-info":[{"award-number":["81930120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ekir.2023.02.1070","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T12:35:00Z","timestamp":1676637300000},"page":"1102-1104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Rituximab as Initial Therapy in Adult Patients With Minimal Change Disease"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-8563","authenticated-orcid":false,"given":"Nan","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-7604","authenticated-orcid":false,"given":"Ruiying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qionghong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Ming","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2023.02.1070_bib1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.ekir.2023.02.1070_bib2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes","volume":"2","author":"Waldman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.02.1070_bib3","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2215\/CJN.01920218","article-title":"Complications of immunosuppression in glomerular disease","volume":"13","author":"Jefferson","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.02.1070_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial","volume":"15","author":"Medjeral-Thomas","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.02.1070_bib5","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1681\/ASN.2016030342","article-title":"Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome","volume":"28","author":"Li","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.02.1070_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/2054358117698667","article-title":"Rituximab in minimal change disease: mechanisms of action and hypotheses for future studies","volume":"4","author":"Madanchi","year":"2017","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.ekir.2023.02.1070_bib7","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.02.1070_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.02.1070_bib9","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/ndt\/gfaa133","article-title":"Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease","volume":"36","author":"Heybeli","year":"2021","journal-title":"Nephrol Dial Transplant"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923011671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923011671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:47:59Z","timestamp":1778892479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024923011671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2468024923011671"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2023.02.1070","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab as Initial Therapy in Adult Patients With Minimal Change Disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.02.1070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}